Nant cancer vaccine
Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
1. A method of treating cancer in a patient in need thereof, the method comprising:
administering to the patient a sequence of therapeutics,
wherein the sequence comprises a platinum chemotherapeutic, Nab-paclitaxel, haNK cells, an antibody for binding PD-L1, and IL-15 or IL-15N72D;
wherein the therapeutics are administered in cycles; and
wherein within the cycle the platinum chemotherapeutic and Nab-paclitaxel are administered before the haNK cells, PD-L1 antibody, and IL-15 or IL-15N72D.
2. The method of claim 1 , wherein the PD-L1 antibody is avelumab.
3. The method of claim 1 , wherein the IL-15N72D is ALT-803.
4. The method of claim 1 , wherein the platinum chemotherapeutic is administered on day 1 of the cycle.
5. The method of claim 4 , wherein the Nab-paclitaxel is administered on days 1 and 15 of the cycle.
6. The method of claim 5 , wherein the haNK cells are administered on day 9 of the cycle.
7. The method of claim 6 , wherein the platinum chemotherapeutic, the PD-L1 antibody, the haNK cells, and the Nab-paclitaxel are administered intravenously (IV), and wherein the ALT-803 is administered subcutaneously.
8. The method of claim 7 , wherein the platinum chemotherapeutic is cisplatin.
9. The method of claim 8 , wherein the cisplatin dose comprises 125 mg.
10. The method of claim 9 , wherein the haNK dose comprises 2×10 9 cells.
11. The method of claim 10 , wherein the antibody dose comprises 10 mg/kg.
12. The method of claim 11 , wherein the ALT-803 dose comprises 10 μg/kg.
13. The method of claim 12 , wherein the sequence further comprises 5-fluorouracil (5-FU).
14. The method of claim 13 , wherein the 5-FU dose comprises 400 mg/m 2 , administered by continuous IV infusion over at least 24 hours.
15. The method of claim 14 , wherein the sequence further comprises doxorubicin.
16. The method of claim 15 , wherein the doxorubicin dose comprises 20 mg/m 2 .
17. The method of claim 16 , wherein the sequence further comprises bevacizumab.
18. The method of claim 17 , wherein the bevacizumab dose comprises 5 mg/kg.
19. The method of claim 18 , wherein the doxorubicin and bevacizumab are administered IV.
20. The method of claim 1 , wherein the cycles are weekly, every two weeks, or every three weeks.